According to the research report titled ‘Sleep Disorder Market Size By Disorder Type (Sleep Apnea {Obstructive Sleep Apnea, Central Sleep Apnea, Complex Sleep Apnea}, Insomnia, Restless Legs Syndrome (RLS), Narcolepsy), By Product (Diagnostics {Actigraphy Systems Polysomnography {PSG} Device, Respiratory Polygraph, Sleep Screening Devices, Home Sleep Tests}, Therapeutics {Cognitive Behavioral Therapy, Therapeutic Devices [Airway Clearance System, Adaptive Servo-ventilation (ASV), Positive Airway Pressure (PAP) Devices, Oral Appliances, Oxygen Devices], Medication Therapy [Benzodiazepines, Dual Orexin Receptor Antagonists, Melatonin Receptor Agonists, Antidepressants, Others]}), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027’, available with MarketStudyReport, global sleep disorder market is anticipated to garner notable returns by the year 2027.

According to reliable sources, growing geriatric population around the world, increasing prevalence of sleeping disorders, as well as rising cases of several lifestyle diseases such as diabetes and obesity are the major growth determinants for sleep disorder
market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4547837/  

Notably, the Covid-19 pandemic has reportedly caused a variety of sleep dysfunctions, including insomnia, disrupted circadian rhythm, and decreased sleep quality in both affected and general populations. Hence, rising prevalence of sleep disorders as a result of the pandemic has encouraged healthcare companies to invest heavily in R&D, which in turn boosted market growth in recent years.

Based on disorder type, the narcolepsy segment held 8% revenue share in worldwide sleep disorder industry in 2020 and is anticipated to grow at a rapid rate over the analysis timeframe, owing to increasing number of narcolepsy diagnoses and treatments.

In terms of product terrain, the diagnostics segment is slated to record a CAGR of 6.9% during the evaluation period, due to growing awareness of sleep disorders among populace, and subsequent surge in demand for diagnostics.

From a regional standpoint, Latin America industry was worth USD 657.9 million in 2020 and is expected to exhibit a robust growth curve throughout the study period, owing to rising prevalence of sleep disorders in the region.

The key players in worldwide sleep disorder market are Teva Pharmaceutical Industries Ltd., Teleflex, Inc., Takeda Pharmaceutical Company Limited, Somnetics International, Inc., ResMed, Inc., Natus Medical Incorporated, Koninklijke Philips N.V., Heptares Therapeutics Ltd., GlaxoSmithKline plc, Ferring International Center SA, Evotec AG, Eisai Co. Ltd., Compumedics Limited, Cardinal Health, Inc., Cadwell Laboratories, Inc., and Astellas Pharma, Inc.